ESTA Stock Forecast & Price Target

Establishment Labs Hldgs is supported by a clear inflection in operating performance, with Q3 revenue of $72.0M rising 34% year over year, adjusted EBITDA of $6.4M, and its first-ever free cash flow positive quarter at $5.1M. The outlook is strengthened by Motiva’s share gains in the U.S., where revenue reached $26.0M, about 2,100 accounts are active, and Preservé adoption is accelerating as more than 400 surgeons were trained and the platform contributed about 17% of U.S. revenue. Management also lifted 2026 revenue guidance to at least $274M and sees further upside from FDA-approved smaller implant sizes, a potential reconstruction label expansion, and a more disciplined international channel that should improve visibility and margins.

Establishment Labs Hldgs is pressured by weak Middle East orders, with no contribution in 1Q26 and no meaningful recovery assumed in 2H26 guidance, while management remains conservative because the region still represents less than 5% of total revenue. The bearish case also rests on poor sales of Motiva, the company’s lead product, alongside the risk of delayed regulatory clearances and launch timing across markets, both of which can slow international growth. In addition, intensified competition from better-capitalized rivals, delayed profitability targets that strain capital, and supply dependence on a single silicone source heighten execution and financial risk.